Moderna and Merck melanoma vaccine combo cuts recurrence or death risk in Phase 3 trial
Detailed Phase 3 results show the personalized mRNA cancer vaccine developed by Moderna and Merck improves outcomes for melanoma patients when used with Keytruda after surgery. The findings, based on more than 1,100 patients and the first two years of follow-up, add to evidence that individualized cancer vaccines may become a new treatment approach.
Highlights
- Moderna and Merck's Phase 3 trial shows their vaccine-Keytruda combo cuts risk of melanoma death or recurrence by 42% and disease spread by 38%.
- After two years, 82.2% of patients on the combination remained cancer-free versus 70% on Keytruda alone, with treatment starting 13 weeks post-surgery.
- Despite exceeding Wall Street expectations, Moderna shares fell over 20% and Merck shares dropped 0.7% Thursday after results leaked before the ESMO presentation.
Phase 3 trial results and treatment design
As reported by Reuters, Moderna and Merck say their vaccine-and-immunotherapy combination reduces the risk of death or recurrence of melanoma by 42% and lowers the risk of the disease spreading by 38% in a late-stage trial.The study compares nine doses of the personalized vaccine, known as intismeran, plus Merck's Keytruda against Keytruda alone, which is a standard melanoma treatment. Treatment begins 13 weeks after surgery to remove melanoma lesions, and the data show 82.2% of patients receiving the combination remain cancer-free after two years, compared with 70% of those given only Keytruda.
The results are scheduled to be presented on Saturday at the European Society for Medical Oncology meeting in Madrid. Moderna and Merck announced in August that the treatment had succeeded, but they did not provide detailed trial data at that time.
Market reaction and broader oncology impact
Investor expectations for the combination were high before the Madrid meeting, with several Wall Street analysts looking for a reduction in recurrence risk of 40% or more. Moderna shares, which have surged since the August announcement, fall more than 20% on Thursday after the results leak earlier in the day on an oncology website, while Merck shares are down about 0.7%.The trial is the first to show that a vaccine tailored to mutations unique to each patient's tumor, combined with a drug that helps the immune system attack cancer, can keep melanoma under control. Dr. Hussein Tawbi, a melanoma expert and trial investigator at the University of Texas MD Anderson Cancer Center, says the findings are highly statistically significant and not due to chance.
In our earlier S&P 500 analysis, we outlined how the index slid amid weakness in technology and semiconductor stocks, alongside worries about the durability of AI-driven investment and the drag from higher borrowing costs. We also highlighted key technical levels, noting SPX trading below its 20- and 50-day moving averages and flagging nearby support/resistance zones as volatility picked up.